- Conditions
- Adult Solid Neoplasm
- Interventions
- Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine, Recombinant Interferon Alfa-2b, Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine, Sargramostim
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 18,603
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heart Septal Defects, Ventricular, Atrioventricular Septal Defect
- Interventions
- IV L-carnitine
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 2 Months to 12 Months
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
- Interventions
- Bexmarilimab, Azacitidine, Venetoclax
- Drug
- Lead sponsor
- Faron Pharmaceuticals Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Duarte, California • New Haven, Connecticut • Chapel Hill, North Carolina + 1 more
- Conditions
- Type 1 Diabetes
- Interventions
- AZD1656
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Vitrectomy
- Interventions
- Dexamethasone Phosphate Ophthalmic Solution
- Drug
- Lead sponsor
- Eyegate Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Sepsis, Respiratory Distress Syndrome, Respiratory Distress Syndrome, Adult
- Interventions
- vasoactive intestinal peptide
- Drug
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 2
- States / cities
- Northport, New York • Stony Brook, New York
- Conditions
- Healthy
- Interventions
- EVP-6308
- Drug
- Lead sponsor
- FORUM Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Neoplasms, Lymphoma
- Interventions
- MLN9708, Nelfinavir
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Steatohepatitis
- Interventions
- Ontamalimab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 15
- States / cities
- Chandler, Arizona • Tucson, Arizona • Coronado, California + 11 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Lenalidomide, Sorafenib
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Hepatitis C, Chronic
- Interventions
- GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a, Ribavirin, Telaprevir
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 18
- States / cities
- Dothan, Alabama • Anaheim, California • Los Angeles, California + 15 more
- Conditions
- Pharmacokinetics of 14C-labeled Isavuconazonium Sulfate, Healthy Subjects
- Interventions
- Pyridinylmethyl-14C-labeled isavuconazonium sulfate
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
- Interventions
- Autologous CD5.CAR/28zeta CAR T cells, Allogeneic CD5.CAR/28zeta CAR T cells
- Genetic
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2040
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- NSCLC, Ovarian Cancer, Melanoma, Other Solid Tumors
- Interventions
- LXH254, PDR001
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Houston, Texas
- Conditions
- Adult Solid Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
- Interventions
- Cilengitide, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Cocaine Dependency
- Interventions
- CPP-115, Placebo
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Adenocarcinoma Pancreas
- Interventions
- PIPAC, Nab-paclitaxel
- Device · Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York
- Conditions
- Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic
- Interventions
- PHIN-214 Subcutaneous injection
- Drug
- Lead sponsor
- PharmaIN
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 9
- States / cities
- Chandler, Arizona • Coronado, California • Marrero, Louisiana + 5 more
- Conditions
- SHANK3 Haploinsufficiency, Phelan-McDermid Syndrome
- Interventions
- JAG201
- Genetic
- Lead sponsor
- Jaguar Gene Therapy, LLC
- Industry
- Eligibility
- 2 Years to 9 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Boston, Massachusetts • New York, New York
- Conditions
- Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
- Interventions
- REM-422
- Drug
- Lead sponsor
- Remix Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- San Francisco, California • Tampa, Florida • Boston, Massachusetts + 4 more
- Conditions
- Pitt Hopkins Syndrome
- Interventions
- MZ-1866
- Genetic
- Lead sponsor
- Mahzi Therapeutics
- Industry
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Oakland, California • Aurora, Colorado • Chicago, Illinois
- Conditions
- Neuroblastoma
- Interventions
- adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH, oral β-glucan
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 374 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV Infections
- Interventions
- Lopinavir/ritonavir, Efavirenz, Lamivudine, Tenofovir DF
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- monoclonal antibody A27.15, monoclonal antibody E2.3
- Biological
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2001
- U.S. locations
- 1
- States / cities
- Tucson, Arizona